Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-γ pathway activation in swine aortic valve endothelium

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 2, 2010, Pages 225-231

  Guerraty, Marie A ^a   Grant, Gregory R ^a   Karanian, John W ^b   Chiesa, Oscar A ^b   Pritchard, William F ^b   Davies, Peter F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cholesterol; Endothelium; Genes; Molecular Biology; Valves

Indexed keywords

ABC TRANSPORTER A1; CASPASE 3; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; AORTA VALVE DISEASE; AORTIC VALVE SCLEROSIS; ARTICLE; BOAR (MALE PIG); ENDOTHELIUM; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; AORTIC VALVE; CASPASE 3; CASTRATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENOTYPE; HEART VENTRICLES; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MALE; NF-KAPPA B; PHENOTYPE; PPAR GAMMA; RNA, MESSENGER; SCLEROSIS; SIGNAL TRANSDUCTION; SUS SCROFA; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75149144852     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.198549     Document Type: Article

References (36)

1. Goldbarg SH, Elmariah S, Miller MA, Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol. 2007;50:1205-1213.
2. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997;29: 630-634.
3. Mohler ER III. Mechanisms of aortic valve calcification. Am J Cardiol. 2004;94:1396-1402, A1396.
4. Durbin AD, Gotlieb AI. Advances towards understanding heart valve response to injury. Cardiovasc Pathol. 2002;11:69-77.
5. Passerini AG, Polacek DC, Shi C, Francesco NM, Manduchi E, Grant GR, Pritchard WF, Powell S, Chang GY, Stoeckert CJ Jr, Davies PF. Coexisting proinflammatory and antioxidative endothelial transcription profiles in a disturbed flow region of the adult porcine aorta. Proc Natl Acad Sci USA. 2004;101:2482-2487.
6. Simmons CA, Grant GR, Manduchi E, Davies PF. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res. 2005;96:792-799.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
8. Butcher JT, Tressel S, Johnson T, Turner D, Sorescu G, Jo H, Nerem RM. Transcriptional profiles of valvular and vascular endothelial cells reveal phenotypic differences: influence of shear stress. Arterioscler Thromb Vasc Biol. 2006;26:69-77.
9. Butcher JT, Nerem RM. Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress. Tissue Eng. 2006;12:905-915.
10. Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res. 2004;95:459-470.
11. Hurle JM, Colvee E. Changes in the endothelial morphology of the developing semilunar heart valves: a TEM and SEM study in the chick. Anat Embryol (Berl). 1983;167:67-83.
12. Maron BJ, Hutchins GM. The development of the semilunar valves in the human heart. Am J Pathol. 1974;74:331-344.
13. Civelek M, Manduchi E, Riley RJ, Stoeckert CJ Jr, Davies PF. Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. Circ Res. 2009;105:453-461.
14. Filip DA, Nistor A, Bulla A, Radu A, Lupu F, Simionescu M. Cellular events in the development of valvular atherosclerotic lesions induced by experimental hypercholesterolemia. Atherosclerosis. 1987;67:199-214.
15. Sorescu GP, Sykes M, Weiss D, Platt MO, Saha A, Hwang J, Boyd N, Boo YC, Vega JD, Taylor WR, Jo H. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem. 2003;278:31128-31135.
16. Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, Boyd NL, Platt MO, Lassegue B, Griendling KK, Jo H. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95:773-779.
17. Kaden JJ, Bickelhaupt S, Grobholz R, Vahl CF, Hagl S, Brueckmann M, Haase KK, Dempfle CE, Borggrefe M. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis. 2004;13:560-566.
18. Hollnagel A, Oehlmann V, Heymer J, Rüther U, Nordheim A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem. 1999;274:19838-19845.
19. Chien W, Kumagai T, Miller CW, Desmond JC, Frank JM, Said JW, Koeffler HP. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem. 2004;279:53087-53096.
20. Gouaze V, Andrieu-Abadie N, Cuvillier O, Malagarie-Cazenave S, Frisach MF, Mirault ME, Levade T. Glutathione peroxidase-1 protects from CD95-induced apoptosis. J Biol Chem. 2002;277:42867-42874.
21. Ran Q, Liang H, Gu M, Qi W, Walter CA, Roberts LJ II, Herman B, Richardson A, Van Remmen H. Transgenic mice overexpressing gluta-thione peroxidase 4 are protected against oxidative stress-induced apo-ptosis. J Biol Chem. 2004;279:55137-55146.
22. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998; 281:1312-1316.
23. Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen RN. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis. J Biol Chem. 2005;280:13600-13605.
24. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, Glass CK. Peroxisome proliferator-acti-vated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol. 1997;17:2166-2176.
25. Ockner RK, Manning JA. Fatty acid-binding protein in small intestine: identification, isolation, and evidence for its role in cellular fatty acid transport. J Clin Invest. 1974;54:326-338.
26. Drori S, Girnun GD, Tou L, Szwaya JD, Mueller E, Xia K, Shivdasani RA, Spiegelman BM. Hic-5 regulates an epithelial program mediated by PPARgamma. Genes Dev. 2005;19:362-375.
27. Wolfrum C, Borrmann CM, Borchers T, Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha-and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci USA. 2001;98:2323-2328.
28. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171.
29. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823-834.
30. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, Giachelli CM. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161:2035-2046.
31. Read MA, Whitley MZ, Williams AJ, Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med. 1994;179:503-512.
32. Zeng Z, Yin Y, Huang AL, Jan KM, Rumschitzki DS. Macromolecular transport in heart valves, I: studies of rat valves with horseradish per-oxidase. Am J Physiol Heart Circ Physiol. 2007;292:H2664-H2670.
33. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res. 2008;102: 283-294.
34. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49:497-505.
35. Sacks MS, Yoganathan AP. Heart valve function: a biomechanical perspective. Philos Trans R Soc Lond B Biol Sci. 2007;362:1369-1391.
36. Chatzizisis YS, Jonas M, Coskun AU, Beigel R, Stone BV, Maynard C, Gerrity RG, Daley W, Rogers C, Edelman ER, Feldman CL, Stone PH. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation. 2008; 117:993-1002.